natgillin/translations-raw huggingface dataset:
is selected from the group consisting of H, a polyethylene glycol polymer wherein n can range between 1 and 5, and R5-C(O)-, wherein R5 is a substituted or non-substituted non-cyclic aliphatic group of C1 to C24, or a substituted or non-substituted alicyclyl group of C1 to C24; and 
je odabran iz skupine koju čine H, polietilen glikol polimer pri čemu n može biti u rasponu između 1 i 5, i R5-C(O)-, pri čemu R5 je supstituirana ili nesupstituirana neciklička alifatska skupina od C1 do C24, ili supstituirana ili nesupstituirana aliciklička skupina od C1 do C24; i
Also in still another embodiment of aspect 3 to be more emphasized, the present invention refers to a salt of (E)-3-[1-(4-dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of L-ascorbic acid, L-aspartic acid, ethanesulfonic acid, glutamic acid, lactic acid such as D-lactic acid or L-lactic acid, malonic acid, cyclamic acid, salicyclic acid, capronic acid, glutaric acid and palmitic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (£)-3-[1-(4- dimetilaminometilbenzensulfonil)-1€-pirol-3-11]-N-hidroksiakrilamida s bilo kojim add kojeg se bira iz skupine koju čine benzensulfonska kiselina, etansulfonska kiselina, glutaminska kiselina, malonska kiselina, naftalen-2sulfonska kiselina, salicilna kiselina, kapronska kiselina, glutarna kiselina i palmitinska kiselina, ili njegov hidrat.
The composition of Claim 1 wherein the MASP-3 monoclonal antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric, and a humanized or human antibody. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se monoklonsko protutijelo protiv MASP-3 ili njegov fragment bira iz skupine koju čini rekombinantno protutijelo, protutijelo sa smanjenom efektorskom funkcijom, kimerno, te humanizirano ili ljudsko protutijelo.
Samples of PET containers of the present disclosure (Samples 3-A, 3-B, 3-C) and of samples of prior art PET containers 1-A, 1-B) were subjected to temperature modulated differential scanning calorimetry (TMDSC) and analyzed in the temperature range of 0°C to 325°C at a heating rate of 5°C/min. 
PET posuda iz patentnog zahtjeva 1 gdje zid, kada je podvrgnut temperaturom moduliranoj diferencijalnoj skenirajućoj kalorimetriji i analiziran u opsegu temperature od 0% C. do 325" C. pri brzini zagrijavanja od 5 *C/min, izlaže temperaturu prvog endotermnog prelaza stakla i temperaturu drugog endotermnog prelaza stakla višu od prve temperature prelaza.
Aqueous use forms can be prepared from emulsion concentrates, suspensions, pastes, wettable powders or water-dispersible granules by adding water. 
Vodcni oblici za primjenu mogu se pripremiti od koncentrata za emulziju, suspenzija, pasta, prašaka koji se mogu vlažiti ii granula koje se mogu raspršivati u vodi, dodavanjem vode.
allowing the mouse to develop an immune response to the antigen of interest; and, identifying a clonally selected lymphocyte of the mouse that expresses an antibody that specifically binds the antigen of interest, and obtaining from the lymphocyte or the antibody a nucleotide sequence that encodes a human heavy chain variable region of the antibody that specifically binds the antigen of interest. 
mišu nedostaje lokus varijabilne regije lakog lanca endogenog mišjeg imunoglobulina koji preuređenjem može tvoriti gen koji kodira varijabilnu regiju k miša; miš eksprimira laki lanac humani imunoglobulina koji je zajednički za više humanih teških lanaca, zajednički laki lanac potječe iz navedenog genskog odsječka varijabilne regije lakog lanca humanog imunoglobulina;
wherein (R1)p is as defined for formula (I), with a compound of formula (III): wherein R3 and R4 are as defined for formula (I) and X is a leaving group, and thereafter optionally: 
reakcije spoja formule (XIV): [image] gdje R1, R2, G i p su kao što je definirano za formulu (I), a X je izlazna skupina, sa spojem formule (V):
The composition for use according to any one of claims 1 to 5, wherein the composition further comprises at least one chelating agent selected from ethylene diamintetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, gdje kompozicija dalje sadrži najmanje jedan helatni agens odabran od etilen diamintetraoctene kiseline (EDTA) 1 etilen glikol tetraoctene kiseline (EGTA).
The process according to embodiment 3, wherein steps (b) and (c) are performed sequentially starting with step (b) followed by step (c). 
Postupak prema zahtjevu 3, gdje se koraci (b) i (c) provode uzastopno tako da se počne s korakom (b) te slijedi korak (c).
A pharmaceutical composition comprising the human engineered DKK-1 antibody or antigen-binding fragment thereof, comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises CDRs LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, wherein LCDR1 is SEQ ID NO: 5, LCDR2 is SEQ ID NO: 8, LCDR3 is SEQ ID NO: 7, HCDR1 is SEQ ID NO: 1, HCDR2 is SEQ ID NO: 2, and HCDR3 is SEQ ID NO:4 together with a pharmaceutically acceptable carrier, diluent, or excipient for use in the treatment of cancer. 
Farmaceutski pripravak koji sadrži ljudsko konstruirano protutijelo protiv DKK-1, ili njegov antigenski vežući fragment, koje sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje LCVR sadrži CDR-e LCDR1, LCDR2, te LCDR3, a HCVR sadrži CDR-e HCDR1, HCDR2, te HCDR3, gdje je LCDRI SEQ ID NO: 5, LCDR2 je SEQ ID NO: 8, LCDR3 je SEQ ID NO: 7, HCDRI je SEQ ID NO: 1, HCDR2 je SEQ ID NO: 2, a HCDR3 je SEQ ID NO:4, uz farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar, naznačen time što je namijenjen upotrebi u liječenju raka.
Oxidation of the so obtained Tyrosol to Hydroxytyrosol in the presence of methylrhenium trioxide and of hydrogen peroxide in a protic solvent; 
oksidaciju tako dobivenog Tyrosola u Hydroxytyrosol u prisutnosti metilrenijeva trioksida u protonskom otapalu;
Compounds of the formula I as claimed in claims 1 to 18 in which W is CH2. 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 18, gdje W je CH2.
Connecting link 11 comprises a measurement unit which, as detailed above, in turn comprises an element for acquiring acceleration data, in particular an acceleration sensor; as well as one or more auxiliary sensors for measuring at least one further physical quantity associated with the anchoring. 
sredstvo za dobivanje podataka o ubrzanju, osobito senzor ubrzanja, ii. = pomoćno senzorsko sredstvo za mjerenje najmanje jedne daljnje fizikalne veličine povezane sa sidrenjem;
After 15 minutes phosphorus oxychloride (0.128 g, 0.83 mmol) was added and the solution heated to 80°C overnight, cooled, filtered, and the collected solid washed with acetonitrile. 
Nakon 15 minuta je dodan fosforni oksiklorid (0.128 g, 0.83 mmol) i otopina je zagrijavana na 80 "C preko noći, ohlađena, filtrirana i sakupljena krutina je isprana acetonitrilom.
Material according to one of Claims 1 to 11, characterized in that it is provided in the form of a powder, of a paste or of a plaster panel. 
Materijal prema jednom od zahtjeva 10 ili 11, naznačen time da je u obliku praška, paste ili gips ploče.
The cores of the prior art have some drawbacks. 
Jezgre ranije tehničke izvedbe imaju izvjesnih mana.
The method according to claim 4, further comprising a dispensing start step and a plate knitting dispensing step, during said plate knitting dispensing step said dispensing end of the body of the second yarn finger being moved, with respect to its position during said dispensing start step, along said direction in accordance with the direction of rotation of the needle cylinder with respect to said feed. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time, da obuhvaća početni korak distribucije i korak distribucije platirnog pletiva, za vrijeme navedenog koraka distribucije platirnog pletiva, navedeni kraj (12) za distribuciju tijela drugog vodiča za predivo (8) se pomiče u odnosu na svoj položaj tijekom navedenog koraka početka distribucije, duž navedenog smjera (14) u skladu sa smjerom okretanja cilindra s iglama (2, 3) u odnosu na navedeni dovod.
The method as claimed in any of claims 19 to 24 wherein said monitoring of said disease comprises determining regression, course or onset of said disease in a sample from a patient who has said disease or is suspected of falling ill with said disease. 
Postupak prema bilo kojem od patentnih zahtjeva 6 do 9 naznačen time što navedeno praćenje navedene bolesti kancera sadrži određivanje regresije, toka ili početka navedene bolesti u uzorku od pacijenta koji ima navedenu bolest ili za koga se sumnja da se razboljeva od navedene bolesti.
the removal by distillation of the above-mentioned unsaponifiable components (b1)-(b3) is performed in such a way as to leave the following unsaponifiable components of the crude tall oil: 
(c) - uklanjanje destiliranjem gore navedenih neosapunjivih komponenata (b1)-(b3) se tako provodi da se ostavi sljedeće neosapunjive komponente sirovog talovog ulja:
disrupting the membrane integrity of the cells in a portion of the cell culture medium containing cells of the tissue-engineered product; 
(c) narušavanja integriteta membrane stanica u dijelu medija stanične kulture koji sadrži stanice produkta preinačenog-tkiva;
a modified phyllosilicate composition comprising a modifying agent which is hexadecyl trimethyl ammonium cations which are intercalated between the layers of the phyllosilicate, and further comprises acetylcholine or choline cations as modifying agent; wherein the acetylcholine or choline is present at a concentration comprised from 0.1 - 1 meq/100g the value of the phyllosilicate cation exchange capacity and the hexadecyl trimethyl ammonium ions are present at a concentration comprised from 0.4 - 9.9 meq/100g the value of the phyllosilicate cation exchange capacity. 
Kompozicija modificiranog filosilikata koja sadrži modificirajuće sredstvo u obliku heksadecil trimetil amonij iona koji su umetnuti između slojeva filosilikata i dodatnog modificirajućeg sredstva izabranog iz grupe koju čine acetilholin i holin; pri čemu je acetilholin ili holin prisutan u koncentraciji sadržanoj od 0.1 - 1 meq/100g vrijednosti kapaciteta kationske izmjene filosilkata i heksadecil trimetil amonija ioni su prisutni u koncentraciji sadržanoj od 0.4 - 9.9 meq/100g vrijednosti kapaciteta kationske izmjene filosilikata.
The straps (24) may consist of a buckle, snap, hook and loop fastener (Velcro), or the like equivalent having an objective of securing the foot to the shell structure (18). 
Prenosiva udlaga za nogu u skladu s patentnim zahtjevom 1, naznačena time što je prednja strana (60) školjkaste strukture (18) pretežno u obliku slova U kako bi se prilagodila i podržavala stopalo, gležanj 1 list osobe.
color component values in the received image data are represented by the set of reference digital code values, the reference digital code values having a bit depth of 10 or 12 bits, 
i Postupak u skladu s patentnim zahtjevom 1, naznačen time što vrijednosti digitalnog koda D imaju bitovnu dubinu od 10 ili 12 bitova.
Corynebacterium glutamicum KCCM 11046 strain useful for the preparation of D-psicose from D-fructose or D-glucose. 
Soj Corynebacterium glutamicum KCCM 11046 naznačen time da je učinkovit za pripremanje D-psikoze iz D-fuktoze ili D-glukoze.
The cover of the present invention can be manufactured in a light material, such as plastics, which is inexpensive and easy to handle. 
Pokrov se prema predloženom izumu može izraditi iz laganog materijala, kao što je plastika, koja nije skupa i s kojom se lako rukuje.
A compound of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, wherein: 
O (D ili stereoizomer, tautomer, farmaceutski prihvatljiva sol ili solvat tog spoja, gdje:
The compound of claim 6 or a pharmaceutically acceptable salt thereof wherein R3, R4 and the carbon atom to which they are attached together form —C3-6cycloalkyl. 
Spoj prema patentnom zahtjevu 6 naznačen time što Rs, Rx i atom ugljika za koji su vezani zajedno formiraju -Ca.sCikloalkil.
The powder composition can be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder can be administered by means of an inhaler. 
Praškasti pripravak može biti u jediničnom dozirnom obliku na primjer u kapsulama ili spremnicima, tj. želatinoznim ili blister pakiranjima iz kojih se prašak može primijeniti inhalacijom.
A method according to claim 1, wherein the melt is provided on to the periphery of the first rotor at a temperature of 1450 to 1575° C., preferably 1480 to 1550° C. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je rastaljeni material postavljen na periferiji prvog rotora na temperaturi od 1450 do 1575"C, preporučljivo 1480 do 1550%C.
wherein Ra and Rb independently represent, at each occurrence, hydrogen, or a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom; and; or a pharmaceutically acceptable solvate or, more particularly, salt thereof; for use in the treatment of osteoporosis and/or osteopenia. 
KHOH=O(CHJCO,H. gdje R* i R* nezavisno predstavljaju, pri svakom pojavljivanju, vodik, ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, 1li heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom; i nje 0, 1, 2,3 ili 4; ili farmaceutski prihvatljiv solvat ili, pobliže, njenu sol; za uporabu u liječenju osteoporoze i/ili osteopenije.
wherein m is selected from the group consisting of 0, 1, 2, or 3; 
Spoj ili sol prema zahtjevu 1, naznačen time, da je m odabran iz skupine koju čine 01 1;
The fungicidal composition according to Claim 1, wherein B is thienyl substituted by Y. 
Fungicidni pripravak u skladu s patentnim zahtjevom 1, naznačen time, da B je tienil supstituiran s Y.
The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: Oxycodone hydrochloride: 10.0 mg/tablet Lactose (spray-dried): 69.25 mg/tablet 
Farmaceutski oblik za doziranje s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu je oblik za doziranje koji sadrži 10 mg oksikodon hidroklorida kada je testiran u usporednoj kliničkoj studiji bioekvivalentan referentnoj tableti koja sadrži 10 mg oksikodon hidroklorida u formulaciji matrice koja sadrži: Oksikodon hidroklorid; 10.0 mg/tableti Laktoza (suho raspršena): 68,25 mg/tableti Povidon: 5.0 mg/tableti Eudragit® RS 30D (krutine): 10.0 mg/tableti Triacetin®: 2.0 mg/tableti Stearil alkohol: 25.0 mg/tableti Talk: 2.5 mg/tableti Magnezijev stearat. 1.25 mg/tableti;
According to one aspect of the present invention, the heterogeneous catalyst may further comprise at least one element selected from the group consisting of Fe, Ni, Co, Cu, Cr, W, Mn, Mo, V, Sn, Zn, Si in an amount up to 20% by weight, such as an amount up to 10% by weight, preferably in an amount up to 5% by weight, such as up to 2.5% by weight. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu heterogeni katalizator nadalje obuhvaća barem jedan element odabran iz grupe koja se sastoji od Fe, Ni, Co, Cu, Cr, W, Mn, Mo, V, Sn, Zn, S1 u količini do 20 % prema težini, kao što je količina do 10 % prema težini, poželjno u količini do 5 % prema težini, kao što je do 2,5 % prema težini.
Hydrolysis rates are calculated at 30 minutes in screening experiments and from the slope of the linear portion of the hydrolysis vs. time curves in characterization studies of a compound of formula I. 
Brzine hidrolize izračunate su za 30 minuta u preglednim eksperimentima, te iz nagiba linearnog dijela krivulje hidroliza-vrijeme u karakterizacijskim ispitivanjima spoja formule I.
The resulting residue was triturated with ether to give the intermediate 18 as a brown solid (0.87 g, 10% yield) and impure product (2.36 g). 
Dobiveni ostatak je trituriran sa eterom da bi se dobio Intermedijer 18 kao smeđe čvrsta supstanca (0.87 g, 10% prinos) i nečisti proizvod (2,36 g).
Tumor inhibition in animal models in vivo 
Inhibicija tumora u životinjskih modela in vivo
providing a discharge which is situated in the center with respect to the annular auxiliary injection line; 
- < izvedba ispusta (28) koji se nalazi u središtu s obzirom na pomoćnu injekcijsku liniju (25),
The binder is preferably added in such an amount that the final preparation contains 2 to 5 wt-% such as 2 to 4.5 wt-%, more preferably 3 to 5 wt-% such as 3 to 4.5 wt-%, and most preferred 3 to 4 wt-% of the binder, based on the total weight of the pharmaceutical composition. 
Vezivo se po mogućnosti dodaje u takvoj količini da konačni pripravak sadrži 2 do 5 %, težinski, primjerice 2 do 4,5 %, težinski, poželjnije 3 do 5 %, težinski, primjerice 3 do 4,5 %, težinski, najpoželjnije 3 do 4 %, težinski, veziva, na osnovu ukupne težine farmaceutskog pripravka.
The method of claim 13 or 14 comprising combining the composition after step (2) with a pharmaceutically acceptable carrier. 
Postupak prema zahtjevu 13 ili 14, naznačen time, da obuhvaća sjedinjavanje sastava s farmaceutski prihvatljivim nosačem nakon koraka (2).
The compound of any one of embodiments 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R1 is C1-6 alkyl, C1-6haloalkyl, C3-6 cycloalkyl, or C3-6 cycloalkyl-C1-3 alkyl, wherein said C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-3 alkyl, are each optionally substituted with 1, 2, or 3 substituents independently selected from fluoro, -CF3, and methyl. The compound of any one of embodiments 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R1 is isopropyl, ethyl, 1-methylpropyl, 2,2,2-trifluoro-1-methylethyl, 1-cyclopropylethyl, cyclopropyl, 1-trifluoromethylcyclopropyl, 1-cyclopropyl-2,2,2-trifluoroethyl, 2,2,2-trifluoroethyl, or 2,2-difluoroethyl. 
HR P20170795 T1 Spoj prema bilo kojem od zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time da: a) R! je Ci alkil, Cig haloalkil, C3.4 cikloalkil, ili C3.4 cikloalkil-C, 3 alkil, pri čemu je svaki od navedenih C;.4 alkil, Ca4 cikloalkil i C,4 cikloalkil-C;.3 alkil, proizvoljno supstituiran s 1, 2, ili 3 supstituenta koji se neovisno biraju između fluoro, -CF> i metil; ili b) R' je izopropil, etil, 1-metilpropil, 2,2,2-trifluoro-1-metiletil, 1-ciklopropiletil, ciklopropil, 1- trifluorometilciklopropil, 1-ciklopropil-2,2,2-trifluoroetil, 2,2,2-trifluoroetil, ili 2,2-difluoroetil; ili c) R! je izopropil, etil, 1-metilpropil, ili 2,2,2-trifluoro-1-metiletil.
in an amount from about 31% to about 33% by weight and the formulation further comprises: 
(c) u količini od 31% do 33% po masi i formulacija dodatno obuhvaća:
is selected from the group consisting of hydrogen, C1-3 alkyl, C3-6 cylcoalkyl, C4-5 alkylcycloalkyl, wherein C1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C1-6 alkoxy; 
X=CHN, NO; R, je izabran iz grupe koja se sastoji od vodika, C,3 alkil, Css cikloalkil, Cy s alkilcikloalkil, gdje je Ci13 alkil izborno supstituiran sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C,.galkoksi;
Typically, solvents are selected from the group consisting of ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol, t-butanol, n-pentanol, tert-pentyl alcohol (tert-amyl alcohol), ethylene glycol, propylene glycol, dipropylene glycerol, diethylene glycol monoethyl ether, tetrahydrofurane, 1,4-dioxane, 1,2-dioxane, 1,3-dioxane and mixtures thereof. 
Postupak prema zahtjevu 7, naznačen time, što se otapalo odabire iz skupine koja se sastoji od etanola, n-propanola, izopropanola, n-butanola, izobutanola, sek-butanola, t-butanola, n-pentanola, terc-pentil alkohola (terc-amil alkohola), etilen glikola, propilen glikola, dipropilen glikola, glicerola, dietilen glikol monoetil etera, tetrahidrofurana, 1,4-dioksana, 1,2-dioksana, 1,3-dioksana i njihovih smjesa.
A pharmaceutical composition according to claim 1 in a suitable form for topical administration. 
Farmaceutski pripravak prema patentnom zahtjevu 10, naznačen time da je u pogodnom obliku za topičko davanje.
Sugar replacement composition, according to a fourth specific embodiment of the invention. Ingredient Minimum relative amount (Weight %) 
Sastavina koja zamjenjuje šećer, prema četvrtoj specifičnoj varijanti, koja nije u skladu s ovim izumom Minimalna relativna Maksimalna relativna
One more preferred class of alkenyl or alkynyl groups has from 2 to about 6 carbon atoms, and most preferably 2, 3 or 4 carbon atoms. 
Jedna poželjnija klasa alkenil ili alkinil grupa ima od 2 do oko 6 atoma ugljika, a najpoželjnije 2, 3 ili 4 atoma ugljika.
A composition for removing a biofilm formed by Staphylococcus aureus, comprising one or more of the bacteriophage or bacteriophage lytic protein selected from the group consisting of bacteriophage SAP- 1 (Accession No: KCTC 11153BP), bacteriophage SAP-2 (Accession No: KCTC11154BP), lytic protein SAL-1 (SEQ ID NO:28), and lytic protein SAL-2 (SEQ ID NO:31). 
Sastav za uklanjanje biofilma stvorenog od Staphylococcus aureusa kao aktivni sastojak sadrži litički protein izveden iz bakteriofaga sposobnog za ubijanje Staphylococcus aureusa specifično i učinkovito u uništavanju biofilma stvorenog od Staphylococcus aureusa, pri čemu litički protein izveden iz bakteriofaga ima aminokiselinski slijed predstavljen SEQ ID NO: 28 ili SEQ ID NO: 31.
a vehicle tire tread sensor; or a vehicle vital fluids sensor, the tool operable to receive data from the sensors. 
senzor za gazni sloj gume vozila (100); ili senzor za vitalne tekućine vozila, gdje alat radi tako da prima podatke iz senzora.
humanized antibodies that comprise a heavy chain variable region having the amino acid sequence of SEQ ID NO: 50 (H0-VH) and a light chain variable region having the amino acid sequence of SEQ ID NO: 52 (L0-VL); and 
(7) protutijelo koje sadržava varijabilnu regiju teškog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 214 (H78) i varijabilnu regiju lakog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 220 (L17) (H78L17);
Other factors must be considered in designing systems to apply such types of substances. 
Moraju se uzeti u obzir i drugi čimbenici kod projektiranja sustava za nanošenje ovih vrsta supstanci.
New stable pentadecapeptide salts of formula (I), wherein basic amino acids are arginine, lysine, ornithine or others, in L-, D- or DL-form, preferably L-arginine. 
Nove stabilne soli pentadekapeptida formule (I), naznačene time, da bazične aminokiseline su arginin, lizin, ornitin ili neke druge, u L-obliku, D-obliku ili DL-obliku, a posebno je to L-arginin.
first microprocessor 6a interrupts data transmission over serial transmission channel 10a; 
prvi mikroprocesor 6a prekida prijenos podataka preko serijskog prijenosnog kanala 10a;
wherein the symbol, when drawn across a bond, indicates the point of attachment to the rest of the molecule. A pharmaceutical composition, comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, carrier, or diluent. 
Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1-21 ili njegova farmaceutski prihvatljiva sol, stereoizomer bilo kojeg od prethodnih, ili njihova smjesa, i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, nosač ili razrjeđivač.